Metabolic syndrome screening: Difference between revisions
Aditya Ganti (talk | contribs) Created page with "__NOTOC__ {{Metabolic syndrome}} {{CMG}} ; {{AE}} {{ADG}} ==Overview== ==Screening== ==References==" |
Aditya Ganti (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Screening== | ==Screening== | ||
According to the Endocrine Society clinical guidelines, screening for metabolic syndrome is recommended every 3 years among patients with one or more risk factors (type 2 DM or with a family history of dyslipidemia, CVD, or hereditary conditions associated with cardiovascular mortality such as polycystic ovary syndrome, and in cases of childhood obesity). Screening assessment includes measurement of:<ref name="pmid18664543">{{cite journal |vauthors=Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R |title=Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline |journal=J. Clin. Endocrinol. Metab. |volume=93 |issue=10 |pages=3671–89 |year=2008 |pmid=18664543 |doi=10.1210/jc.2008-0222 |url=}}</ref> | |||
*Blood pressure | |||
*Waist circumference | |||
*Fasting lipid profile, and fasting glucose. | |||
==References== | ==References== | ||
Revision as of 12:47, 14 September 2017
|
Metabolic syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Metabolic syndrome screening On the Web |
|
American Roentgen Ray Society Images of Metabolic syndrome screening |
|
Risk calculators and risk factors for Metabolic syndrome screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Screening
According to the Endocrine Society clinical guidelines, screening for metabolic syndrome is recommended every 3 years among patients with one or more risk factors (type 2 DM or with a family history of dyslipidemia, CVD, or hereditary conditions associated with cardiovascular mortality such as polycystic ovary syndrome, and in cases of childhood obesity). Screening assessment includes measurement of:[1]
- Blood pressure
- Waist circumference
- Fasting lipid profile, and fasting glucose.
References
- ↑ Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R (2008). "Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline". J. Clin. Endocrinol. Metab. 93 (10): 3671–89. doi:10.1210/jc.2008-0222. PMID 18664543.